Arcturus Q1 net loss $51.2M ($1.94/share); ARCT-154 booster shows 54-fold Omicron BA.1 response

Arcturus Therapeutics Holdings Inc.

2023-Q1 EPS reported -$1.94 revenue$5,244,000

Q1 2022 revenue $5.2M (up from $2.1M YoY); operating expenses $55.6M; net loss $51.2M.
Cash $319.7M at March 31, 2022; expected to fund operations into late 2023.
ARCT-154 booster data: 54-fold and 46-fold GMFR against Omicron BA.1 and BA.2 at Day 29.
Primary vaccine efficacy 95.3% against severe COVID-19; 55% overall; 98.4% seroconversion.
ARCT-810 Phase 2 OTC deficiency trial to start Q2 2022; ARCT-032 cystic fibrosis CTA filing on track for Q3 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.